Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Triptorelin - Debiopharm

Next Previous
X
Search
Drug Profile

Triptorelin - Debiopharm

Alternative Names: ARVEKAP; AY 25650; BIM 21003; BN 52014; CL 118532; Debio 8200; Debio 8206; debio8200; Decapeptyl; Decapeptyl SR; Decapeptyl® LP; Diphereline; Gonapeptyl; Moapar; Pamorelin; Pamorelin LA; Salvacyl; Trelstar; Trelstar Depot; Triptodur; Triptorelin acetate; Triptorelin embonate; Triptorelin pamoate; Triptoreline; Tryptorelin; WY 42422

Latest Information Update: 03 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tulane University
  • Developer AbbVie; Arbor Pharmaceuticals; Debiopharm; European Organisation for Research and Treatment of Cancer; Ipsen; Orient Europharma; United Laboratories
  • Class Antineoplastics; Antivirals; Infertility therapies; Oligopeptides; Pituitary hormone releasing hormones
  • Mechanism of Action Gonadotropin releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Precocious puberty
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Endometriosis; Female infertility; Paraphilias; Precocious puberty; Prostate cancer; Uterine leiomyoma
  • Phase II Salivary gland cancer
  • No development reported Malignant melanoma

Most Recent Events

  • 20 Aug 2024 Ipsen completes a phase-III trial in Prostate cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IM), (NCT05590793)
  • 08 Jul 2024 Ipsen completes phase-III TriptoSwitch trial in Prostate cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Spain, Netherlands, Lithuania, Germany, France, Czech Republic, Belgium (SC) (NCT05458856)
  • 23 Apr 2024 Endo International has been acquired and merged into Endo, Inc.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top